NDATOPICALLOTION
Approved
Nov 2018
Lifecycle
Peak
Competitive Pressure
0/100
Clinical Trials
1
Data completeness
5/8 — Partial
Drug data last refreshed 13h ago · AI intelligence enriched 2w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
BRYHALI is a topical lotion formulation of halobetasol propionate, a potent corticosteroid indicated for inflammatory skin conditions. It is applied directly to affected skin areas to reduce inflammation, itching, and dermatological manifestations. The drug works through topical corticosteroid receptor binding to suppress local immune and inflammatory responses.
$0.142MPart D
Peak5.0 years to LOEProduct is at peak commercial maturity with modest Part D utilization; commercial team focus is on maintaining market position ahead of LOE.
Mechanism of Action
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Clinical Trials (1)
Combination of Halobetasol Propionate and Tazarotene Lotion (Duobrii®) for Palmoplantar Plaque Type Psoriasis
Started Nov 2020
22 enrolled
Palmoplantar PsoriasisPlaque Psoriasis
Why This Matters for Your Career
Worked on BRYHALI at Bausch + Lomb? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.